A comparative review of Haute Autorité de Santé and National Institute for Health and Care Excellence health technology assessments of Ikervis® to treat severe keratitis in adult patients with dry eye disease which has not improved despite treatment with tear substitutes

References

• Smith JA, Albeitz J, Begley C, et al. The epidemiology of dry eye disease: report of the epidemiology subcommittee of the International Dry Eye WorkShop. Ocul Surf. 2007 Apr;5(2):1–12.
   Web of Science ®Google Scholar
• Lemp M, Baudouin C, Baum J, et al. The definition and classification of dry eye disease: report of the definition and classification subcommittee of the International Dry Eye Workshop. Ocul Surf. 2007 Apr;5(2):75–92.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Flamion B, Baudouin C. Keratitis in dry eye disease and topical ciclosporin A. Ocul Immunol Inflamm. 2017 Feb;1:1–10.
   Google Scholar
• Wei Y, Asbell P. The core mechanism of dry eye disease (DED) is inflammation. Eye Contact Lens. 2014 Jul;40(4):248–256.
   PubMed Web of Science ®Google Scholar
• Sullivan B, Crews L, Messmer E, et al. Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implications. Acta Ophthalmol. 2014 Mar;92(2):161–166.
   PubMed Web of Science ®Google Scholar
• Chi GY. Some issues with composite endpoints in clinical trials. Fundam Clin Pharmacol. 2005 Dec;19(6):609–619. Review.
   PubMed Web of Science ®Google Scholar
• Schein OD, Tielsch JM, Munõz B, et al. Relation between signs and symptoms of dry eye in the elderly. A population-based perspective. Ophthalmology. 1997 Sep;104(9):1395–1401.
   PubMed Web of Science ®Google Scholar
• Caparas VL. Medical management of dry eye, in Dry Eye A Practical Approach. Berlin Heidelberg: Springer-Verlag; 2015. p. 51–66.
   Google Scholar
• Baudouin C, Aragona P, Van Setten G, et al. Diagnosing the severity of dry eye: a clear and practical algorithm. Br J Ophthalmol. 2014 Sep;98(9):1168–1176.
   PubMed Web of Science ®Google Scholar
• Bron A. The definition and classification of dry eye disease, in Dry Eye A Practical Approach. Berlin Heidelberg: Springer-Verlag; 2015. p. 1–20.
   Google Scholar
• Vehof J, Sillevis Smitt-Kamminga N, Nibourg S, et al. Predictors of discordance between symptoms and signs in dry eye disease. Ophthalmology. 2017 Mar;124(3):280–286.
   PubMed Web of Science ®Google Scholar
• Mantelli F, Massaro-Giordano M, Macchi I, et al. The cellular mechanisms of dry eye: from pathogenesis to treatment. J Cell Physiol. 2013 Dec;228(12):2253–2256.
   PubMed Web of Science ®Google Scholar
• Lienert JP, Tarko L, Uchino M, et al. Long-term natural history of dry eye disease from the patient’s perspective. Ophthalmology. 2016 Feb;123(2):425–433.
   Web of Science ®Google Scholar
• Schiffman RM, Walt JG, Jacobsen G, et al. Utility assessment among patients with dry eye disease. Ophthalmology. 2003 Jul;110(7):1412–1419.
   PubMed Web of Science ®Google Scholar
• Sullivan RM, Cermak JM, Papas AS, et al. Economic and quality of life impact of dry eye symptoms in women with Sjoegren’s syndrome. Adv Exp Med Biol. 2002;506(Pt B):1183–1188.
   Google Scholar
• McDonald M, Patel DA, Keith MS, et al. Economic and humanistic burden of dry eye disease in Europe, North America, and Asia: a systematic litterature review. Ocul Surf. 2016 Apr;14(2):144–167.
   PubMed Web of Science ®Google Scholar
• Clegg JP, Guest JF, Lehman A, et al. The annual cost of dry eye syndrome in France, Germany, Italy, Spain, Sweden and the UK among patients managed by ophthalmologists. Ophthalmic Epidemiol. 2006 Aug;13(4):263–274.
   Web of Science ®Google Scholar
• Yu J, Asche CV, Fairchild JC. The economic burden of dry eye disease in the USA: a decision tree analysis. Cornea. 2011 Apr;30(4):379–387.
   PubMed Web of Science ®Google Scholar
• Pflugfelder S, Geerling G, Kinoshita S, et al. Management and therapy of dry eye disease: report of the management and therapy subcommittee of the International Dry Eye Workshop. Ocul Surf. 2007 Apr;5(2):163–178.
   PubMed Web of Science ®Google Scholar
• Ambrosio RJ, Faria Correia F, Ramos I, et al. Artificial tears, in dry eye - a practical approach. Berlin Heidelberg: Springer-Verlag. ; 2015. p. 45–50.
   Google Scholar
• Sacchetti M, Mantelli F, Lambiase A, et al. Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease. Br J Ophthalmol. 2014 Aug;98(8):1016–1022.
   PubMed Web of Science ®Google Scholar
• Barber L, Pflugfelder S, Tauber J, et al. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. 2005 Oct;112(10):1790–1794.
   PubMed Web of Science ®Google Scholar
• Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular and systemic corticosteroids. Curr Opin Ophthalmol. 2000 Dec;11(6):478–483.
   Google Scholar
• Kaswan RL, Salisbury MA. A new perspective on canine keratoconjunctivitis sicca. Treatment with ophthalmic cyclosporine. Vet Clin North Am Small Anim Pract. 1990 May;20(3):583–613.
   Web of Science ®Google Scholar
• Palmer SL, Bowen PA, Green K. Longitudinal tear study after cyclosporine in kidney transplant recipients. Ophthalmology. 1996 Apr;103(4):670–673.
   Web of Science ®Google Scholar
• PubMed. [ cited 2016 Jul 30]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/?term=cyclosporine+and+dry+eye
   Google Scholar
• Drosos AA, Skopouli FN, Costopoulos JS, et al. Cyclosporin A in primary Sjoegren’s syndrome: a double-blind study. Ann Rheum Dis. 1986 Sep;45(9):732–735.
   Web of Science ®Google Scholar
• Kaswan RL, Salisbury MA, Ward DA. Spontaneous canine Keratoconjunctivitis Sicca. A useful model for human Keratoconjunctivitis Sicca: treatment with cyclosporine eye drops. Arch Ophthalmol. 1989 Aug;107(8):1210–1216.
   PubMedGoogle Scholar
• Williams DL. A comparative approach to topical cyclosporine therapy. Eye (Lond). 1997;11(Pt 4):453–464.
   PubMed Web of Science ®Google Scholar
• Laibovitz RA, Solch S, Andriano K, et al. Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca. Cornea. 1993 Jul;12(4):315–323.
   PubMed Web of Science ®Google Scholar
• Gündüz K, Ozdemir O. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren’s syndrome. Acta Ophthalmol (Copenh). 1994 Aug;72(4):438–442.
   PubMed Web of Science ®Google Scholar
• CHMP. CHMP Assessment Report - Ikervis. [ cited 2015 Jan 22]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002066/WC500186592.pdf
   Google Scholar
• Schuster E, Schneider S. Ciclosporin-Augentropfen verordnen: wie geht das in der Praxis? Der Augenarzt. 2015 Feb;1. Heft: 23–24.
   Google Scholar
• Chast F, Lemare F, Legeais JM, et al. Preparation d’un collyre de ciclosporine a 2%. J Fr Ophtalmol. 2004 Jun;27(6 Pt 1):567–576.
   Web of Science ®Google Scholar
• Allergan shares tumble following setback with FDA. Los Angeles Times. Jul 22. Available from: http://articles.latimes.com/1999/jul/22/business/fi-58465.
   Google Scholar
• Labbe A, Baudouin C, Ismail D, et al. Pan-European survey of the topical ocular use of cyclosporine A. J Fr Ophtalmol. 2017 Mar;40(3):187–195.
   Web of Science ®Google Scholar
• Fiscella RG, Le H, Lam TT, et al. Stability of cyclosporine 1% in artificial tears. J Ocul Pharmacol Ther. 1996 Spring;12(1):1–4.
   Web of Science ®Google Scholar
• GfK. The use of cyclosporine A preparations and Restasis® in Europe. Data on File. Mar 2013.
   Google Scholar
• Restasis PI. [ cited 2013 Jun]. Available from: https://www.allergan.com/assets/pdf/restasis_pi.pdf.
   Google Scholar
• SmPC Ikervis. Available from: https://ec.europa.eu/health/documents/community-register/2015/20150319131066/anx_131066_en.pdf.
   Google Scholar
• Leonardi A, Van Setten G, Amrane M, et al. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016 Jun 10;26(4):287–296.
   PubMed Web of Science ®Google Scholar
• Commission de la Transparence (HAS). Avis. Ikervis 1mg/ml, eye drops in emulsion. [cited 2015 Sep 09]. Available from: https://www.has-sante.fr/portail/upload/docs/evamed/CT-14365_IKERVIS_PIC_INS_Avis3_CT14365.pdf
   Google Scholar
• NICE. Technology Appraisal Guidance: ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears. Technology appraisal guidance. nice.org.uk/guidance/ta369. [cited 2015 Dec 16]. Available from: https://www.nice.org.uk/guidance/ta369
   Google Scholar
• Massetti M, Aballea S, Videau Y, et al. A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments. J Mark Access Health Policy. 2015 Mar;12;3:1-10.
   Google Scholar
• Center for Economic Studies - Ifo Institute. Choice of relevant comparator to assess added therapeutic benefit or incremental cost-effectiveness ratio of pharmaceuticals. DICE Database. Munich; 2013. Available from: http://www.cesifo-group.de/DICE/fb/yU57iAYV
   Google Scholar
• AFSSAPS. Resume du rapport d’analyse des preparations hospitalieres declarees a l’AFSSAPS (periode janvier 2008/janvier 2010). [ cited 2016 Aug 07]. Available from: http://ansm.sante.fr/Activites/Preparations-hospitalieres/Declaration-des-preparations-hospitalieres
   Google Scholar
• Kauss Hornecker M, Charles Weber S, Brandely Piat ML, et al. Collyres de ciclosporine: etude d’une cohorte de patients de 2009 a 2013. J Fr Ophtalmol. 2015 Oct;38(8):700–708.
   Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. FDA, Center for Drug Evaluation and Research (CDER), Office of Compliance/OUDLC. Compounded drug products that are essentially copies of a commercially available drug product under Section 503A of the Federal Food, Drug, and Cosmetic Act: guidance for the industry. [cited 2016 Jul]. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM510154.pdf
   Google Scholar
• Minghetti P, Pantano D, Gennari CG, et al. Regulatory framework of pharmaceutical compounding and actual developments of legislation in Europe. Health Policy. 2014 Sep;117(3):328–333.
   Web of Science ®Google Scholar
• Gudeman J, Jozwiakowski M, Chollet J, et al. Potential Risks of Pharmacy Compounding. Drugs R D. 2013 Mar;13(1):1–8.
   PubMedGoogle Scholar
• Hall K, Stewart T, Chang J, et al. Characteristics of FDA drug recalls: a 30-month analysis. Am J Health Syst Pharm. 2016 Feb 15;73(4):235–240.
   Web of Science ®Google Scholar
• Huque MF, Alosh M, Bhore R. Addressing multiplicity issues of a composite endpoint and its components in clinical trials. J Biopharm Stat. 2011 Jul;21(4):610–634.
   PubMed Web of Science ®Google Scholar
• Bartlett JD, Keith MS, Sudharshan L, et al. Associations between signs and symptoms of dry eye disease: a systematic review. Clin Ophthalmol. 2015 Sep;16(9):1719–1730.
   Google Scholar
• Davis CE. Secondary endpoints can be validly analyzed, even if the primary endpoint does not provide clear statistical significance. Control Clin Trials. 1997 Dec;18(6):557–560. discussion 561-7.
   Google Scholar
• HAS. Le service medical rendu (SMR) et l’amelioration du service medical rendu (ASMR). [ cited 2016 Aug 06]. Available from: http://www.has/sante-sante.fr/portail/jcms/r_1506267/fr
   Google Scholar
• Schoonveld E. The price of global health: drug pricing strategies to balance patient access and the funding of innovation. Chapter 21. 2nd ed. France: Gower Publishing Limited; 2015. p. 349–359.
   Google Scholar
• Sall KN, Cohen SM, Christensen MT, et al. An evaluation of the efficacy of a cyclosporine-based dry eye therapy when used with marketed artificial tears as supportive therapy in dry eye. Eye Contact Lens. 2006 Jan;32(1):21–26.
   PubMedGoogle Scholar
• Lallemand F, Felt-Baeyens O, Besseghir K, et al. Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm. 2003 Nov;56(3):307–318.
   PubMed Web of Science ®Google Scholar
• Lallemand F, Daull P, Benita S, et al. Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. J Drug Deliv. 2012; 2012:604204.
   Google Scholar
• Nourry H, Perrot S, Martin C, et al. Etude de la cytotoxicite de differents collyres a base de cyclosporine A buvable (Sandimmun). J Fr Ophtalmol. 2006 Mar;29(3):251–257.
   Web of Science ®Google Scholar
• European Commission. Better medicine for children from concept to reality: progress report on the Pediatric Regulation (EC) no1901/2006. Available from: http://ec.europa.eu/health/files/paediatrics/2013_com443/paediatric_report-com(2013)443_en.pdf. 2013.
   Google Scholar
• Abbas KM, Dorratoltaj N, O’Dell ML, et al. Clinical response, outbreak investigation, and epidemiology of the fungal meningitis epidemic in the United States: systematic review. Disaster Med Public Health Prep. 2016;10(1):145–151.
   PubMed Web of Science ®Google Scholar